How the AI Lobbying Boom Is Reshaping Healthcare Policy

AI lobbying has exploded to over $130 million in K Street revenue, with the healthcare sector at the center of policy battles over payer oversight, FDA regulation, and state preemption. This article breaks down who is spending, what they want, and how lobbying dollars are shaping healthcare AI policy.

By Editorial TeamUpdated Jul 21, 2026

AI lobbying reached a different scale

AI lobbying is no longer a niche on K Street. Public Citizen counted 3,570 federal lobbyists working AI issues in 2025, equal to 26% of all registered federal lobbyists and up 168% from 2022, while Bloomberg Government said AI-related lobbying revenue for K Street firms topped $130 million in 2025, including $37.2 million in Q4 alone. [1][2]

That scale matters because it changes who gets a seat at the drafting table. Once AI lobbying becomes a default line item, the fight stops being about whether the technology gets attention and starts being about which regulation gets softened, delayed, or moved to another layer of government.

Stethoscope over glowing digital circuits with faint Capitol and hospital silhouettes.

Healthcare is where the numbers become politically useful

Bloc	Reported figure	What it signals
AI issues on K Street	3,570 federal lobbyists working AI issues in 2025, 26% of all registered lobbyists, up 168% since 2022 [1]	AI became a major federal lobbying lane
Hospital industry	$116.13M in federal lobbying in 2024 across 355 organizations [3]	Hospitals are inside the lobbying field, not outside it
Health and FIRE AI-active firms	$503M in combined lobbying expenditures in 2025, including non-healthcare entities [4]	Healthcare-adjacent money is large enough to compete with tech
Big Tech	11 entities spent $41M in H1 2026 [5]	Platform companies still have deep federal reach

The overlap is the point. The health-and-FIRE figure is broad enough to include non-healthcare entities, which is exactly why it matters for healthcare policy: the filings do not sort cleanly by sector, but the implementation burden still lands on hospitals, payers, and state regulators. [4]

Federal wins so far

Industry has already secured deregulatory ground in Washington, including the revocation of the Biden AI executive order. A proposed 10-year freeze on state AI action did not become settled law, leaving a lighter federal baseline and more room for states to write their own healthcare AI rules.

Split image showing federal deregulatory symbols on one side and stricter state oversight symbols on the other.

Where the real implementation burden lands

That split shows up most clearly in payer AI oversight and FDA device regulation. In prior authorization and claims review, the question is who can use AI, what gets disclosed, and who answers when the model steers care or payment the wrong way. At the FDA, the issue is how much evidence a model needs before it is treated as a clinical device instead of a piece of software. Those are not abstract lobbying themes; they are the points where a vague policy line turns into workload for hospital compliance teams, payer operations staff, and state regulators.

The policy field is already fragmented. Federal pressure can keep one lane loose, while states are building healthcare AI oversight on their own timetable. The result is a patchwork shaped by who is spending, which issue lane they are buying, and which layer of government is likely to answer back.

References

One in Four Federal Lobbyists Now Work on AI — Public Citizen, Feb. 2026
AI influence spending booms, signaling monumental clashes ahead — Bloomberg Government, Mar. 2026
Hospital industry lobbying in 2024 — PMC/NIH, 2025
AI lobbying: defense industry — OpenSecrets, Feb. 2026
Lobbying disclosures reveal Big Tech spends more than $226,000 per day to buy influence — Issue One, July 2026